BIOREGENX Business Summary

BIOREGENX, INC. (OTC: BRGX) is a health-technology holding company specializing in non-invasive diagnostics and AI-driven predictive analytics for microvascular and metabolic health. The company generates revenue through a diversified model comprising direct sales of medical hardware, recurring diagnostic test fees, and high-margin software-as-a-service (SaaS) licensing. Its primary business segments include Medical Testing, centered on the patented GlycoCheck® vascular imaging platform; Nutritional Products, featuring the clinically validated Endocalyx Pro™ supplement; and AI-Driven Vital Sign Detection, following the 2025 integration of DocSun Biomedical Holdings. This ecosystem is further supported by SDK licensing partnerships and a legacy social media content management platform (Findit.com). Direct competitors include Vaso Corporation, NuraLogix, and Binah.ai; BioRegenx maintains a unique market position by being the only provider to integrate real-time endothelial glycocalyx measurement with contactless AI vital-sign monitoring. The leadership team is led by Co-founder, CEO, and Chairman William "Bill" Resides, an experienced sales executive and entrepreneur who previously co-founded NuLife Sciences and held leadership roles at Loop Media and Resides Enterprises. The executive suite includes Finance Consultant Dan Cortes, a CPA with over 25 years of experience including a tenure at KPMG, and Corporate Secretary Gary Hennerberg, a marketing strategist and author who has consulted for Fortune 500 companies such as Dow Chemical and Eli Lilly. The company is advised by the law firm Sichenzia Ross Ference Carmel LLP, with Partner Ross Carmel supporting its 2026 corporate uplisting strategy. Notable institutional backing includes investment from Hatchworks, while the company’s scientific foundation is built upon research validated by over 140 peer-reviewed studies.